GLP-1 therapies begin with motivation, long-term success depends on what happens when that motivation fluctuates.
This case study explores how Mighty, the AI health assistant within MyTherapy’s scalable direct-to-patient (DTP) ecosystem, protects persistence at predictable risk moments across the treatment lifecycle.
Inside the case study:
- Where GLP-1 persistence declines in real-world programs, and why traditional metrics miss it
- Why reminder-based adherence models are insufficient for long-term metabolic care
- How to address behavioral and emotional risk moments at scale without increasing compliance burden
- What a scalable, brand-ready DTP persistence architecture looks like across markets
Download the full case study to learn how GLP-1 programs can sustain long-term therapy persistence!
